Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.

Anal Chem

Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.

Published: January 2016

Structural characterization was performed on an antibody-drug conjugate (ADC), composed of an IgG1 monoclonal antibody (mAb), mertansine drug (DM1), and a noncleavable linker. The DM1 molecules were conjugated through nonspecific modification of the mAb at solvent-exposed lysine residues. Due to the nature of the lysine conjugation process, the ADC molecules are heterogeneous, containing a range of species that differ with respect to the number of DM1 per antibody molecule. The DM1 distribution profile of the ADC was characterized by electrospray ionization mass spectrometry (ESI-MS) and capillary isoelectric focusing (cIEF), which showed that 0-8 DM1s were conjugated to an antibody molecule. By taking advantage of the high-quality MS/MS spectra and the accurate mass detection of diagnostic DM1 fragment ions generated from the higher-energy collisional dissociation (HCD) approach, we were able to identify 76 conjugation sites in the ADC, which covered approximately 83% of all the putative conjugation sites. The diagnostic DM1 fragment ions discovered in this study can be readily used for the characterization of other ADCs with maytansinoid derivatives as payload. Differential scanning calorimetric (DSC) analysis of the ADC indicated that the conjugation of DM1 destabilized the C(H)2 domain of the molecule, which is likely due to conjugation of DM1 on lysine residues in the C(H)2 domain. As a result, methionine at position 258 of the heavy chain, which is located in the C(H)2 domain of the antibody, is more susceptible to oxidation in thermally stressed ADC samples when compared to that of the naked antibody.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.5b03709DOI Listing

Publication Analysis

Top Keywords

ch2 domain
12
structural characterization
8
dm1
8
lysine residues
8
antibody molecule
8
diagnostic dm1
8
dm1 fragment
8
fragment ions
8
conjugation sites
8
conjugation dm1
8

Similar Publications

Polycyclic tetramate macrolactams (PoTeMs) represent a growing class of bioactive natural products that are derived from a common tetramate polyene precursor, lysobacterene A, produced by an unusual bacterial iterative polyketide synthase (PKS) / non-ribosomal peptide synthetase (NRPS). The structural and functional diversity of PoTeMs is biosynthetically elaborated from lysobacterene A by pathway-specific cyclizing and modifying enzymes. This results in diverse core structure decoration and cyclization patterns.

View Article and Find Full Text PDF

This study investigates the contributions of non-bonding energy (NBE) to the efficacy of four HDAC4 co-crystallized inhibitors (HA3, 9F4, EBE, and TFG) through 100ns Molecular Dynamics (MD) simulations. These inhibitors contain hydroxamic acid (HA3, 9F4, EBE) or diol (TFG) as zinc-binding groups. In PDBs 2VQJ and 2VQM, the HDAC4 catalytic domain is in the 'open' conformation, while in PDBs 4CBT and 6FYZ, the same is in the 'closed' conformation.

View Article and Find Full Text PDF

Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications.

Mol Pharm

December 2024

Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430207, China.

Article Synopsis
  • In the pharmaceutical industry, Chinese hamster ovary cells are commonly used to produce traditional monoclonal antibodies, while nanobodies like C-type nanoantibodies (C-Nabs) are emerging as promising next-generation drugs.
  • The study evaluated various expression systems (bacteria, yeast, mammalian cells) for producing C-Nabs, assessing their binding, stability, and resistance to degradation.
  • Results indicated that yeast is the most effective host for producing C-Nabs, which showed better pharmacokinetic properties when tested in mice, supporting their potential as therapeutic candidates.
View Article and Find Full Text PDF

Human immunoglobulin G (IgG) antibodies are one of the most important classes of biotherapeutic agents and undergo glycosylation at the conserved N297 site in the C2 domain, which is critical for IgG Fc effector functions and anti-inflammatory activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. While attempts to engineer for this purpose have been described, they have met limited success due in part to the lack of available oligosaccharyltransferase (OST) enzymes that can install linked glycans within the QYNST sequon of the IgG C2 domain.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers analyzed donkey milk IgG using RP-UHPLC-MS/MS to examine its specific glycosylation patterns, revealing the presence of multiple subtypes.
  • Proteomic analysis showed that various IgG subtypes (IgG1, IgG2, IgG3, IgG5, IgG6, and IgG7) had unique glycopeptides linked to a conserved glycosylation site in their heavy-chain regions.
  • Notably, IgG5 exhibited a distinct glycosylation pattern with sialylated glycans, while structural diversity was primarily seen in IgG1, IgG5, and IgG7, highlighting the potential functional properties of donkey milk.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!